Lightnews — Scholar-powered news

Chordoma Foundation Labs @cflabsresearch.bsky.social · 19d

Huge congrats and thanks to the team behind this foundational study, particularly Caty Lee-Chang, JP Wolinsky, Victor Arrieta, Jessica Du and colleagues. We're excited to work with them and others to bring targeted immunotherapy to chordoma patients building on these new insights!

Chordoma Foundation Labs @cflabsresearch.bsky.social · 19d

- Demonstrates tumor-specific antigen recognition by tumor-resident and peripheral T cells, suggesting potential for adoptive T cell strategies

1 1

Chordoma Foundation Labs @cflabsresearch.bsky.social · 19d

- Suggests important roles for myeloid cells in regulating anti-tumor immunity, consistent with several prior studies but providing additional nuance
- Identifies several potential mechanisms of immune evasion in chordoma and suggests potential strategies for overcoming this evasion

1

Chordoma Foundation Labs @cflabsresearch.bsky.social · 19d

In brief, it:
- Provides the largest spatial data set to date including single cell RNA-seq, TCR profiling and multiplex immunoflourescence
- Reveals three distinct patterns of immune cell composition in chordoma tumors, potentially pointing to a need for treatment strategies tailored for each

1

Chordoma Foundation Labs @cflabsresearch.bsky.social · 19d

Important new paper from @neurosurgerynm.bsky.social and several collaborators reveals critical features of the chordoma immune landscape and lays the foundation for chordoma patients to benefit from immunotherapy advances. 🧵

academic.oup.com/neuro-oncolo...

Integrated Immune Profiling of Chordomas Reveals Spatially Organized Niches and Functional Heterogeneity

AbstractBackground. Chordomas are locally aggressive notochordal tumors with no systemic therapy options. As an ultra-rare cancer type, our understanding o

academic.oup.com

1

Chordoma Foundation Labs @cflabsresearch.bsky.social · Aug 14

Latest negative result: Response of chordoma cell lines to treatment with the KIF18A inhibitor sovilnesib (AMG 650), as a single agent and in combination with gemcitabine figshare.com/articles/fig...

Response of chordoma cell lines to treatment with the KIF18A inhibitor sovilnesib (AMG 650), as a single agent and in combination with gemcitabine

To evaluate KIF18A inhibitors as a potential therapeutic target, chordoma cell lines were treated with sovilnesib. A panel of four chordoma cell lines was seeded in a white-walled 96-well plate so tha...

figshare.com

Chordoma Foundation Labs @cflabsresearch.bsky.social · Aug 14

monitoring the situation as a shipment of precious chordoma samples from our biobank flys to Melbourne for our collaborators in the Firestein lab at @hudsonresearch.bsky.social ✈️ 🇦🇺

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jul 29

- PKMYT1 inhibitor Lunresertib
- BRG1/BRM inhibitor FHD-286
- DNA Polymerase θ inhibitor ART558
- Aurora A kinase inhibitor Alisertib
- DNA-PK inhibitor M3814
- PRMT5 inhibitor AMG 193
- GCL inhibitors, Target 831-P2 and Target S, S-408-P2

1 1

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jul 29

Positive results are celebrated, but we think sharing negative results is important too. In case helpful to anyone, here are compounds we tested in vitro in recent months which didn't show substantial activity as single agents or synergy with known active compounds:

figshare.com/authors/Chor...

Chordoma Foundation

figshare.com

1 1

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jun 19

We’re hiring for a new role on our research team. It'll be an opportunity to advance interesting science, to work in a nimble and empowering environment, and, to make a tangible impact in the lives of patients in urgent need of new treatment options. www.linkedin.com/jobs/view/42...

Chordoma Foundation hiring Director of Preclinical Research in Durham, NC | LinkedIn

Posted 12:34:07 PM. The Chordoma Foundation is seeking an experienced and high-agency individual to support the…See this and similar jobs on LinkedIn.

www.linkedin.com

Chordoma Foundation Labs @cflabsresearch.bsky.social · May 6

The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma
pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...

The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma

The aim of this research was to investigate the pathogenesis of the bone cancer chordoma and the role of the germline rs2305089 SNP in TBXT. Using medical imaging and genotyping studies, we observed ....

pathsocjournals.onlinelibrary.wiley.com

Chordoma Foundation Labs @cflabsresearch.bsky.social · Mar 22

We’re excited about the potential of your team’s approach!

Reposted by Chordoma Foundation Labs

Daniel Alvarez @daninthenet.bsky.social · Mar 4

Interesting new challenge similar in spirit to the well known CACHE!!

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 22

For all the gains AI affords in compound design and discovery, experimental validation still remains a bottleneck. But we're making that part easy for the cancer target TBXT with a suite of biophysical, in vitro and in vivo assay capabilities—plus prizes for potent binders: tbxtchallenge.org

1 1 2

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 22

For all the gains AI affords in compound design and discovery, experimental validation still remains a bottleneck. But we're making that part easy for the cancer target TBXT with a suite of biophysical, in vitro and in vivo assay capabilities—plus prizes for potent binders: tbxtchallenge.org

3 2

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 22

Congrats @ghazivakili.bsky.social! If the ability to experimentally verify your model's performance for another currently undruggable target would be helpful, we can make that easy for the transcription factor TBXT—and we're offering a prize for discovery of potent ligands: tbxtchallenge.org

TBXT CHALLENGE – Make history in drug discovery

Make history in drug discovery

tbxtchallenge.org

1

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 22

Congrats @jchodera.bsky.social! If the ability to experimentally verify your models' performance for a currently undruggable target would be of interest, we can make that easy for the transcription factor TBXT—and we're offering a prize if the model identifies potent ligands: tbxtchallenge.org

TBXT CHALLENGE – Make history in drug discovery

Make history in drug discovery

tbxtchallenge.org

1 1

Reposted by Chordoma Foundation Labs

The Institute of Cancer Research @icr.ac.uk · Feb 15

📰 Prof Paul Workman, our former CEO, along with his team in our Centre for Cancer Drug Discovery, have made a breakthrough that could lead to new drugs for #chordoma — a rare #BoneCancer that led to the death of his mother.

Read more in @theguardian.com ⤵️

www.theguardian.com/science/2025...

British professor makes ‘thrilling’ breakthrough for cancer that killed his mother

Paul Workman has researched untreatable chordoma for years. Now new technology points towards to a potential drug to beat it

www.theguardian.com

3 8 39

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 16

So others don't have to reinvent the wheel, we've developed and offer capabilities to support TBXT drug discovery including purified protein production, SPR and various functional assays. For more info see below or get in touch: [email protected] www.chordomafoundation.org/researchers/...

Catalyzing TBXT Drug Discovery

TBXT, also called Brachyury, is a key driver and genetic dependency of chordoma, and is associated with disease progression in various other tumor types.…

www.chordomafoundation.org

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 16

We're excited to see how others build on these data including to compete in the TBXT Challenge (offering >$500K in prizes for more potent binders) tbxtchallenge.org

TBXT CHALLENGE – Make history in drug discovery

Make history in drug discovery

tbxtchallenge.org

1

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 16

Crucial building blocks for drugging TBXT (brachyury) published by @ox.ac.uk @icr.ac.uk @uncchapelhill.bsky.social team including crystal structure, discovery of ligandable pockets, and compounds that could serve as starting points for inhibitors or degraders www.nature.com/articles/s41...

Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy - Nature Communications

This study describes structures of the transcription factor brachyury revealing the mechanism of DNA recognition. They identify fragments using X-ray fragment screening and optimize these into potent ...

www.nature.com

2 4 8

Reposted by Chordoma Foundation Labs

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jan 10

#chemsky & #compchem peeps, we need your help drugging a difficult target: TBXT (brachyury), a transcription factor critical for our disease, chordoma, and implicated in other cancers. We can offer enabling resources, free SPR analysis and now $500K+ in prizes for TBXT ligands: tbxtchallenge.org

TBXT CHALLENGE – Make history in drug discovery

Make history in drug discovery

tbxtchallenge.org

2 4 7

Chordoma Foundation Labs @cflabsresearch.bsky.social · Feb 7

Congrats! This is an exciting approach. Any interest in giving it a try on a transcription factor? We can perform SPR for binding to the cancer associated TF TBXT and are offering prizes for compounds with <1uM Kd. tbxtchallenge.org

TBXT CHALLENGE – Make history in drug discovery

Make history in drug discovery

tbxtchallenge.org

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jan 10

If you're interested in competing or have questions or suggestions, we'd love to hear from you. Please get in touch at [email protected].

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jan 10

We hope this competition will not only accelerate discovery of urgently needed TBXT drugs, but may also serve as an opportunity to validate technologies and approaches capable of addressing other undruggable targets.

1

Chordoma Foundation Labs @cflabsresearch.bsky.social · Jan 10

We invite companies and academic investigators to submit up to 96 compounds for free biophysical evaluation. Results will be returned confidentially and competitors retain ownership of their IP and data.

1